Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $15.8 million.

  • Monte Rosa Therapeutics' Non-cash Items rose 28238.72% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 28238.72%. This contributed to the annual value of $11.4 million for FY2024, which is 19110.66% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Non-cash Items stood at $15.8 million for Q3 2025, which was up 28238.72% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non-cash Items peaked at $15.8 million during Q3 2025, and registered a low of $3.4 million during Q3 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Non-cash Items value was $5.4 million (recorded in 2024), while the average stood at $7.5 million.
  • In the last 5 years, Monte Rosa Therapeutics' Non-cash Items crashed by 6317.71% in 2024 and then soared by 28238.72% in 2025.
  • Monte Rosa Therapeutics' Non-cash Items (Quarter) stood at $4.7 million in 2023, then soared by 140.86% to $11.4 million in 2024, then soared by 38.03% to $15.8 million in 2025.
  • Its Non-cash Items was $15.8 million in Q3 2025, compared to $8.1 million in Q2 2025 and $7.5 million in Q1 2025.